65,437 trials
Macular Edema · Central Retinal Vein Occlusion · Hemiretinal Vein Occlusion
Primary: Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 — 16.9; 17.3 ETDRS Letters — p=0.6715
Moderate to Severe Chronic Plaque Psoriasis
Primary: • To Evaluate Efficacy of DMB-3115 in Comparison With Stelara — 77.5; 77.85; 87.59; 87.89 percent change in PASI score
Communication · Critical Illness
Primary: Perceived Acceptability Comparison of CICU TALC by CICU Providers Immediately After Completion of Intervention: Satisfaction Survey — 1.4 score on a scale
Healthy Adult Subjects
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and…
HIV
Primary: Change in Proportion of Viral Load Suppression (<=200 Copies/mL) — 327; 314 Participants — p=0.86
Covid19 · Vaccine Refusal
Primary: Difference in Proportion of Participants "Likely to Vaccinate" Between Study Arms at Month 1 — 1; 3 Participants
Haemophilia A
Primary: Number of Bleeding Episodes Per Year (Annualised Bleeding Rate) — 0.00; 0.00 Bleeding episodes per year
Infertility, Female
Primary: Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS)…
Mild Traumatic Brain Injury (mTBI) · Post-traumatic Stress Disorder
Primary: Change in Abnormal Magnetoencephalography (MEG) Slow-Waves (1-4 Hz) Activity — 1.8; 0.2; 0 units on a scale — p=0.01
Multiple Sclerosis
Primary: Cerebral Metabolic Rate of Oxygen (CMRO2) — 165.84; 128.3; 159.4 µmol/100g/min
Colonoscopy · Bowel Preparation · Endoscopy
Primary: Percentage of Subjects With Successful Bowel Preparation — 175; 132; 137 Participants — p=<0.001
Glaucoma, Open-Angle
Primary: Mean Intraocular Pressure — 21.8; 20.5; 23.4; 19.7 mmHg
Menstruation
Primary: The Percentage of Used Tampons That Have Elongated — 2; 75; 4; 48 tampons
Pain
Primary: Quantity of Narcotic Utilized by Patient for Pain in Milligrams at 240 Minutes — 2.66; 3.7 mg
Malignant Melanoma
Primary: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…